Mutaions and carcinogenesis
Keywords:
gene mutations, mutations, cancer, carcinogenesisAbstract
There are two types of gene mutations, namely, hereditary gene mutations and somatic mutations. Both types of mutations imposed the risk of developing cancer. However, cancers caused by hereditary mutations are less common, compared to cancers caused by somatic mutations. Association between gene mutations and carcinogenesis has been suggested by several studies on various types of cancer.Examples of some gene mutations associated with the carcinogenesis are H-ras oncogene, insulin-like growth factor-1,vascular endothelial growth factor A gene, telomerase reverse transcriptase gene, retinoblastoma tumor suppressor gene 1, CDH1 gene.The objective of this review article is to provide up-to-date knowledge about the relationship between gene mutations and carcinogenesis.
References
Watson J, Crick F. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid. Nature 1953;171:737-38.
Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways, and clinical translation for targeted cancer therapy. Sig Transduct Target Ther 2021;6:254.
Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. NPJ Precis Oncol 2019;3:7-21.
Butera A, Melino G, Amelio I. Epigenetic Drivers of Cancer. J Mol Biol 2021;23:433(15) doi: 10.1016/j.jmb.2021.167094.
Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;144(5):646-74.
Alberts B, Hopkin K, Johnson A, Morgan D, Raff M, Roberts K, et al. Essential Cell Biology. Fifth Edition. London: W. W. Norton & Company; 2019.
Dupont C, Armant R D, Brenner CA. Epigenetics: Definition, Mechanisms and Clinical Perspective. Semin Reprod Med 2009;27(5):351-57.
Q W Chen, X Y Zhu, Y Y Li, Z Q Meng. Epigenetic regulation and cancer. Oncol Rep 2013;31:523-32.
National Cancer Institute, 2021. NCI Dictionary of Cancer Terms. [Online]
Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/epigenetic-alteration [Accessed 22 June 2022].
Alberts B, Heald R, Johnson A, Morgan D, Raff M, Roberts, et al. Molecular biology of the cell. 7th edition. New York: W. W. Norton & Company; 2022.
Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017;136:665-77.
Gupta M, Wu H, Arora S, Gupta A, Chaudhary G, Hua Q. Gene mutation classification through text evidence facilitating cancer tumour detection. J Healthc Eng 2021.doi:10.1155/ 2021/8689873.
Bork K, Wulff K, Steinmüller-Magin L, Brænne I, Staubach-Renz P, Witzke G, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018;73(2):442-50.
Sadikovic B, Al-Romaih K, Squire JA, Zielenska M. Causes and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics 2008;9(6):394-408.
Campbell CD, Eichler EE. Properties and rates of germline mutations in humans. Trends Genet 2013;29(10):575-84.
Gupta M, Wu H, Arora S, Gupta A, Chaudhary G, Hua Q. Gene mutation classification through text evidence facilitating cancer tumour detection. J Healthc Eng 2021.doi:10.1155 /2021/8689873.
Rodríguez-Martín C, Robledo C, Gómez-Mariano G, Monzón S, Sastre A, Abelairas J, et al. Frequency of low-level and high-level mosaicism in sporadic retinoblastoma: genotype–phenotype relationships. J Hum Genet 2020;65:165-74.
National Academy of Sciences. Heritable Human Genome Editing. 1st ed. Washington DC: The National Academies Press. 2021.
Poirier M C. Chapter 1 The Role of DNA Damage in Cancers Caused by Chemicals. In: M. C. Poirier, ed. Carcinogens, DNA Damage and Cancer Risk. Bethesda(MD):World Scientific 2018;392.
Kufel-Grabowska J, Podolak A, Maliszewski D, Bartoszkiewicz M, Ramlau R, Lukaszuk K. Fertility counseling in BRCA1/2-mutated women with breast cancer and healthy individuals. J Clin Med 2022;11(14):3996-4011.
National Cancer Institure. The Genetics of Cancer. [Online] Available athttps://www.cancer.gov/
about-cancer/causes-prevention/genetics. 2017 [Accessed 19 July 2022].
Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E et al. Therapeutic Implications of Germline Testing in Patients with Advanced Cancers. Journal of Clinical Oncology. 2021;39:2698-2709.
De Almeida LC, Calil FA, Machado-Neto JA, Costa-Lotufo LV. DNA Damaging Agents and DNA Repair: From Carcinogenesis to Cancer Therapy. Cancer Genet 2020;252-253:6-24.
Z Rahal, A Sinjab, II Wistuba, H Kadara. Game of clones: Battles in the field of carcinogenesis. Pharmacology & Therapeutics 2022;237:108251.
Ganini, C, Amelio, I, Bertolo R, Bove P, Buonomo O C, Candi E et al. Global mapping of cancers: The Cancer Genome Atlas and beyond. Mol Oncol 2021;15(16):2823-2840.
Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. J Cell Sci 2018;121(Suppl 1):1-84.
Nordling CO. A new theory on cancer-inducing mechanism. Br J Cancer 1953;7:68-72.
Ashley DJ. The two “hit” and multiple “hit” theories of carcinogenesis. Br J Cancer 1969;23:313-28.
Knudson AG. Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 1996;122:135-40.
Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. PNAS 1971;68:820-23.
El Bali M, Bakkach J, Mechita MB. Colorectal cancer: from genetic landscape to targeted therapy. J Oncol 2021.doi.org/10.1155/2021/9918116.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
Greenman C, Stephens P, Smith R, Dalgliesh G L, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-58.
Greenman C, Stephens P, Smith R, Dalgliesh G L, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-58.
Bignell G R, Santarius T, Pole JC, Butler AP, Perry J, Pleasance E, et al. Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res 2007;17:1296-1303.
Sonnenschein C, Soto AM. Somatic Mutation Theory of Carcinogenesis: Why It Should Be Dropped and Replaced. Mol carcinog 2000;29:205-11.
Brucher BL, Jamall IS. Somatic Mutation Theory-Why it’s Wrong for Most Cancers. Cell Physiol Biochem 2016;38:1663-80.
Cho Kj, Liang JR, Crespo Aran. Editorial: Ras and Other GTPases in Cancer: From Basic to Applied Research. Front Mol Biosci 2021;8:804-18
Shetu S A, Bandyopadhyay D. Small-molecule RAS inhibitors as anticancer agents: discovery, development, and mechanistic studies. Int J Mol Sci 2022.doi:10.3390/ijms23073706.
Song D, Cismas S, Crudden C, Trocme E, Worrall C, Suleymanova N, et al. IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma. Oncogene 2022;41:600-11.
Shan Y, Lu C, Wang J, Li M, Ye S, Wu S, et al. IGF-1 contributes to liver cancer development in diabetes patients by promoting autophagy. Ann Hepatol 2022;27(4).doi.org/10.1016/j.aohep.2022.100697.
Vella V, Francesco E M D, Bonavita E, Lappano R, Belfiore A. IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis. Trends Endocrinol Metab 2022;33(8):569-86.
Yodhaanjali JR, Achar RR. Molecular facets and biochemical cross-talk of angiogenesis: Potential therapeutic targets. BBRJ 2022;6(2):159-63.
Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 2016;15:385-403.
Jafri MA, Ansari SA, Alqahtani M. H, Shay J. W. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med 2016;20:8(1):69.doi:10.1186/s 13073-016-0324-x.
Trybek T, Kowalik A, Góźdź S, Kowalska A.Telomeres and telomerase in oncogenesis (Review). Oncol Lett 2020;20:1015-27.
Kroupa M, Rachakonda K S, Liska V, Srinivas N, Urbanova M, Jiraskova K, et al. Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis. Br J Cancer 2019;121:344-50.
Robinson NJ, Schiemann WP. Telomerase in Cancer: Function, Regulation, and Clinical Translation. Cancers (Basel) 2022;14(3):808-23.doi10.3390/ijms23073706.
Quazi S. Telomerase gene therapy: a remission toward cancer. Med Oncol 2022;39:105-28.
Flores M, Goodrich DW. Retinoblastoma Protein Paralogs and Tumor Suppression. Front Genet 2022;13. doi:10.3389/fgene.2022.818719.
Thomas S, Balan A. Retinoblastoma Tumor Suppressor Gene: An Overview. IAOMR (2012);24(1):30-35.
Sagar, Shanmugam M. Genetics of retinoblastoma. In: H. V. Nema & N. Nema, eds. Genetics of ocular diseases. Singapore: Springer 2022;89-99.
Mendonsa A M, Na TY, Gumbin B M. E-cadherin in contact inhibition and cancer. Oncogene 2018;37:4769-80.
Aban CE, Lombardi A, Neiman G, Biani MC, La Greca A, Waisman A, et al. Downregulation of E-cadherin in pluripotent stem cells triggers partial EMT. Sci Rep 2021;11.doi:10.1038/s41598-021-81735-1
Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol 2007;1(1):26-41.
Downloads
Published
Versions
- 2023-01-04 (3)
- 2023-01-04 (2)
- 2022-12-31 (1)
Issue
Section
License
Copyright (c) 2022 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
